Nuveen’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $59.9M | Buy |
1,054,633
+116,064
| +12% | +$5.15M | 0.01% | 612 |
|
|
2026
Q1 | $27.9M | Sell |
938,569
-55,044
| -6% | -$1.65M | 0.01% | 947 |
|
|
2025
Q4 | $38M | Sell |
993,613
-85,078
| -8% | -$2.77M | 0.01% | 782 |
|
|
2025
Q3 | $25.8M | Sell |
1,078,691
-115,644
| -10% | -$2.17M | 0.01% | 988 |
|
|
2025
Q2 | $17.7M | Sell |
1,194,335
-9,309
| -0.8% | -$154K | ﹤0.01% | 1180 |
|
|
2025
Q1 | $21.6M | Sell |
1,203,644
-539,546
| -31% | -$11M | 0.01% | 1086 |
|
|
2024
Q4 | $30.4M | Sell |
1,743,190
-88,913
| -5% | -$1.57M | 0.01% | 908 |
|
|
2024
Q3 | $25.6M | Buy |
1,832,103
+1,094,465
| +148% | +$11.4M | 0.01% | 1020 |
|
|
2024
Q2 | $6.06M | Buy |
737,638
+6,260
| +0.9% | +$42.2K | ﹤0.01% | 1848 |
|
|
2024
Q1 | $5.64M | Buy |
731,378
+247,050
| +51% | +$2.08M | ﹤0.01% | 1928 |
|
|
2023
Q4 | $4.35M | Sell |
484,328
-220,975
| -31% | -$1.61M | ﹤0.01% | 2059 |
|
|
2023
Q3 | $6.31M | Sell |
705,303
-185,474
| -21% | -$2.62M | ﹤0.01% | 1748 |
|
|
2023
Q2 | $13.7M | Buy |
890,777
+563,124
| +172% | +$10.2M | ﹤0.01% | 1315 |
|
|
2023
Q1 | $7.37M | Buy |
327,653
+143,585
| +78% | +$3.05M | ﹤0.01% | 1662 |
|
|
2022
Q4 | $4.54M | Sell |
184,068
-225,420
| -55% | -$4.78M | ﹤0.01% | 1968 |
|
|
2022
Q3 | $10.1M | Sell |
409,488
-27,469
| -6% | -$710K | ﹤0.01% | 1467 |
|
|
2022
Q2 | $10.8M | Buy |
436,957
+28,988
| +7% | +$729K | ﹤0.01% | 1453 |
|
|
2022
Q1 | $10.1M | Sell |
407,969
-9,855
| -2% | -$262K | ﹤0.01% | 1634 |
|
|
2021
Q4 | $10.3M | Sell |
417,824
-58,721
| -12% | -$1.65M | ﹤0.01% | 1671 |
|
|
2021
Q3 | $11.8M | Sell |
476,545
-196,772
| -29% | -$3.62M | ﹤0.01% | 1667 |
|
|
2021
Q2 | $16.6M | Sell |
673,317
-193,909
| -22% | -$3.82M | ﹤0.01% | 1512 |
|
|
2021
Q1 | $21.4M | Buy |
867,226
+106,204
| +14% | +$2.93M | 0.01% | 1268 |
|
|
2020
Q4 | $18.8M | Buy |
761,022
+44,871
| +6% | +$1.05M | 0.01% | 1304 |
|
|
2020
Q3 | $13.2M | Buy |
716,151
+120,618
| +20% | +$2.34M | 0.01% | 1333 |
|
|
2020
Q2 | $12.2M | Buy |
595,533
+34,000
| +6% | +$541K | ﹤0.01% | 1356 |
|
|
2020
Q1 | $8.19M | Buy |
561,533
+4,547
| +0.8% | +$68.4K | ﹤0.01% | 1418 |
|
|
2019
Q4 | $7.91M | Sell |
556,986
-16,089
| -3% | -$206K | ﹤0.01% | 1730 |
|
|
2019
Q3 | $6.64M | Sell |
573,075
-137,386
| -19% | -$2.27M | ﹤0.01% | 1803 |
|
|
2019
Q2 | $14.3M | Buy |
+710,461
| New | +$14M | 0.01% | 1378 |
|
Other funds holding TVTX
JT
PA
NAMI
Nuveen's TVTX Position: Q2 2026 in Review
Nuveen increased its Travere Therapeutics (TVTX) stake by 12% in Q2 2026, buying an estimated $5.15M and bringing the position to 1,054,633 shares worth $59.9M. The position accounts for 0.01% of the portfolio, ranked #612.
Nuveen first reported a position in TVTX in Q2 2019 and has held it in 29 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- Nuveen held 1,054,633 shares of Travere Therapeutics worth $59.9M as of Q2 2026.
- Nuveen bought 116,064 Travere Therapeutics shares in Q2 2026, an estimated $5.15M.
- Travere Therapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #612 holding.
- Nuveen first reported a position in Travere Therapeutics in Q2 2019 and has held it in 29 quarters since.
- 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.